BrainStorm to Present NurOwn® Phase 3 Study Update at the 9th Annual California ALS Research Summit in Irvine, CA
January 11 2019 - 12:05AM
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in
developing innovative autologous cellular therapies for highly
debilitating neurodegenerative diseases, announced today announced
that Ralph Kern MD, MHSc, Chief Operating Officer and Chief Medical
Officer, will provide a clinical update for the ongoing phase 3
pivotal trial of NurOwn® in ALS patients at the 9th Annual
California ALS Research Summit in Irvine, California.
The California ALS Research Summit is an annual
meeting of researchers, investigators, clinicians, biotech
companies, government representatives, partner organizations, and
advocates in ALS and related fields in California.
9th Annual California ALS Research
Summit Details:
Date:
Friday, January 11, 2019
Time:
2:00-2:30pm Pacific Time
Location:
Arnold and Mabel Beckman Center of the
National Academy of Sciences
Agenda:
https://sites.google.com/a/alsagoldenwest.org/california-als-research-summit/schedule
About NurOwn®
NurOwn® (autologous MSC-NTF) cells represent a
promising investigational therapeutic approach to targeting disease
pathways important in neurodegenerative disorders. MSC-NTF cells
are produced from autologous, bone marrow-derived mesenchymal stem
cells (MSCs) that have been expanded and differentiated ex vivo.
MSCs are converted into MSC-NTF cells by growing them under
patented conditions that induce the cells to secrete high levels of
neurotrophic factors. Autologous MSC-NTF cells can effectively
deliver multiple NTFs and immunomodulatory cytokines directly to
the site of damage to elicit a desired biological effect and
ultimately slow or stabilize disease progression. BrainStorm
is currently conducting a Phase 3 pivotal trial of autologous
MSC-NTF cells for the treatment of amyotrophic lateral sclerosis
(ALS). BrainStorm also recently received U.S. FDA acceptance to
initiate a Phase 2 open-label multicenter trial in progressive
Multiple Sclerosis (MS) and plans to start enrollment in early
2019.
About BrainStorm Cell Therapeutics
Inc.
BrainStorm Cell Therapeutics Inc. is a
leading developer of innovative autologous adult stem cell
therapeutics for debilitating neurodegenerative diseases. The
Company holds the rights to clinical development and
commercialization of the NurOwn® technology platform used to
produce autologous MSC-NTF cells through an exclusive, worldwide
licensing agreement. Autologous MSC-NTF cells have received Orphan
Drug status designation from the U.S. Food and Drug
Administration (U.S. FDA) and the European Medicines
Agency (EMA) in ALS. BrainStorm is currently enrolling a Phase
3 pivotal trial in ALS (NCT03280056), investigating
repeat-administration of autologous MSC-NTF cells at six sites in
the U.S., supported by a grant from the California Institute
for Regenerative Medicine (CIRM CLIN2-0989). The pivotal study
is intended to support a filing for U.S. FDA approval of
autologous MSC-NTF cells in ALS. For more information, visit
BrainStorm's website at www.brainstorm-cell.com.
Safe-Harbor
Statements
Statements in this announcement other than historical data and
information constitute "forward-looking statements" and involve
risks and uncertainties that could cause BrainStorm Cell
Therapeutics Inc.'s actual results to differ materially from
those stated or implied by such forward-looking statements. Terms
and phrases such as "may", "should", "would", "could", "will",
"expect", "likely", "believe", "plan", "estimate", "predict",
"potential", and similar terms and phrases are intended to identify
these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on
Form 10-Q available at http://www.sec.gov. These factors
should be considered carefully, and readers should not place undue
reliance on BrainStorm's forward-looking statements. The
forward-looking statements contained in this press release are
based on the beliefs, expectations and opinions of management as of
the date of this press release. We do not assume any obligation to
update forward-looking statements to reflect actual results or
assumptions if circumstances or management's beliefs, expectations
or opinions should change, unless otherwise required by law.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance or
achievements.
CONTACTSMedia: Joseph Petroziello BrainStorm
Cell Therapeutics Phone: +1.215.485.6797
Email: JP@brainstorm-cell.com
Investors: Marcy Beth Nanus Solebury Trout Phone:
+1.646.378.2927 Email: MNanus@troutgroup.com
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Feb 2024 to Mar 2024
Brainstorm Cell Therapeu... (NASDAQ:BCLI)
Historical Stock Chart
From Mar 2023 to Mar 2024